enGene Therapeutics Inc. (ENGN)

Market Cap	570.08M +148.5%
Revenue (ttm)	n/a
Net Income	-122.44M
EPS	-2.22
Shares Out	66.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173,553
Open	8.58
Previous Close	8.53
Day's Range	8.29 - 8.65
52-Week Range	2.65 - 12.25
Beta	-0.05
Analysts	Buy
Price Target	21.08 (+147.71%)
Earnings Date	Jun 11, 2026

About ENGN

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 82
• Stock Exchange: NASDAQ
• Ticker Symbol: ENGN
• Website: https://www.engene.com

Analyst Summary

According to 6 analysts, the average rating for ENGN stock is "Buy." The 12-month stock price target is $21.08, which is an increase of 147.71% from the latest price.

Price Target

$21.08

(147.71% upside)

Analyst Consensus: Buy